LEADER 01126nam0 22002893i 450 001 SUN0092413 005 20130110122351.725 010 $a88-14-02966-0 100 $a20130110d1991 |0itac50 ba 101 $aita 102 $aIT 105 $a|||| ||||| 200 1 $aˆLe ‰imposte sui redditi nel Testo Unico$eaggiornamento al 30 aprile 1991$fMaurizio Leo, Felice Monacchi, Mario Schiavo 205 $a2. ed. agg. e ampl.$fcon la collaborazione di Giuseppe Roxas 210 $aMilano$c Giuffré$d1991 215 $aXIII, 143 p.$d26 cm. 620 $dMilano$3SUNL000284 700 1$aLeo$b, Maurizio$3SUNV010990$0232056 701 1$aMonacchi$b, Felice$3SUNV010993$0232543 701 1$aSchiavo$b, Mario$3SUNV010994$0232544 702 1$aRoxas$b, Giuseppe$3SUNV074493 712 $aGiuffrè$3SUNV001757$4650 801 $aIT$bSOL$c20181231$gRICA 912 $aSUN0092413 950 $aUFFICIO DI BIBLIOTECA DEL DIPARTIMENTO DI ECONOMIA$d03PREST Iv\Gd 11 $e03 644 20130110 996 $aImposte sui redditi nel Testo unico$962672 997 $aUNICAMPANIA LEADER 04683nam 22005535 450 001 9910350356703321 005 20200702082709.0 010 $a981-13-7383-3 024 7 $a10.1007/978-981-13-7383-1 035 $a(CKB)4100000008876787 035 $a(DE-He213)978-981-13-7383-1 035 $a(MiAaPQ)EBC5780747 035 $a(PPN)236520873 035 $a(EXLCZ)994100000008876787 100 $a20190527d2019 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aHigh-Density Lipoproteins as Biomarkers and Therapeutic Tools $eVolume 2. Improvement and Enhancement of HDL and Clinical Applications /$fby Kyung-Hyun Cho 205 $a1st ed. 2019. 210 1$aSingapore :$cSpringer Singapore :$cImprint: Springer,$d2019. 215 $a1 online resource (XVI, 268 p. 174 illus.) 311 $a981-13-7382-5 327 $aChapter 1. Improvement of HDL -- 1-1.Clinical application of HDL: Overview -- 1-2.Regression effect of V156K-apoA-I -- 1-3.Anti-diabetic effect of V156K-apoA-I -- 1-4.Vitamin C and HDL -- 1-5.Growth hormone-1 in HDL -- 1-6.Growth hormone-2 in HDL -- 1-7.Omega-3 and HDL -- Chapter 2. HDL as therapeutic tools -- 2-1.Delivery vehicle for therapeutics : Overview -- 2-2.Gene delivery: adenovirus and V156K-apoA-I -- 2-3.Solubilization of rapamycin and delivery -- 2-4.Solubilization of minoxidil and delivery -- Chapter 3. Enhancement of HDL by policosanol: anti-aging and longevity -- 3-1.Policosanol and HDL functionality -- 3-2.Policosanol and raising HDL in zebrafish -- 3-3.Policosanol and CETP inhibition: human trial 8 weeks -- 3-4.Policosanol and blood pressure lowering: human trial 8 weeks -- 3-5.Policosanol blood pressure lowering human trial for 24 weeks -- 3-6.Policosanol and improvement of aortic stiffness -- 3-7.Policosanol and blood pressure lowering in rat model -- 3-8.Twelve week consumption of policosanol and lowering blood pressure -- 3-9.Publication analysis of policosanol-related studies -- 3-10.Athero-protective effects of policosanol and sugar cane wax acid -- 3-11.Cuban sugarcane wax acids and policosanol improved serum lipid profiles -- Summary and perspectives -- Epilogue. 330 $aThis book is the second of two volumes that offer a comprehensive, up-to-date account of current knowledge regarding high-density lipoprotein (HDL), the changes that occur in HDL under different conditions, the clinical applications of HDL, and means of enhancing HDL functionality. In this volume, the focus is on the improvement of HDL, enhancement of its functionality, and the use of HDL for therapeutic purposes. In the first section, up-to-date information is provided on such topics as the tumor regression-promoting and antidiabetic activities of reconstituted HDL containing V156K apolipoprotein A-I, the enhancement of HDL effects by high doses of vitamin C, the benefits derived from incorporation of growth hormones 1 and 2 into rHDL, and the biological functions of omega-3 linolenic acid in rHDL. The enhancement of HDL functionality by policosanol and the resultant benefits are thoroughly examined in a separate section. Readers will also find the latest information on clinical applications of HDL. Here, specific topics include the enhancement of adenoviral gene delivery and the delivery of rapamycin. In documenting the latest knowledge in this field, this volume will be of interest to both researchers and clinicians. 606 $aMolecular biology 606 $aPharmaceutical technology 606 $aBiomedical engineering 606 $aDiabetes 606 $aMolecular Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/B1700X 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 606 $aBiomedical Engineering/Biotechnology$3https://scigraph.springernature.com/ontologies/product-market-codes/B24000 606 $aDiabetes$3https://scigraph.springernature.com/ontologies/product-market-codes/H33045 615 0$aMolecular biology. 615 0$aPharmaceutical technology. 615 0$aBiomedical engineering. 615 0$aDiabetes. 615 14$aMolecular Medicine. 615 24$aPharmaceutical Sciences/Technology. 615 24$aBiomedical Engineering/Biotechnology. 615 24$aDiabetes. 676 $a611.01816 700 $aCho$b Kyung-Hyun$4aut$4http://id.loc.gov/vocabulary/relators/aut$0952601 906 $aBOOK 912 $a9910350356703321 996 $aHigh-Density Lipoproteins as Biomarkers and Therapeutic Tools$92153528 997 $aUNINA